Brain Imaging: Cocaine Effects & Medication Development - 5

This study has been completed.

First Received on September 20, 1999. Last Updated on August 16, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	New York State Psychiatric Institute
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000270

Purpose

The purpose of this study is to define temporal profile of brain activation (rCBF) using Xenon-SPECT and O 15-PET.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Cocaine	Phase IV

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Brain Imaging: Cocaine Effects & Medication Development

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Absolute change in rCBF at 5 & 15 minutes (Xe)
Relative change in rCBF at 5, 19, & 33 minutes (O15)
Correlated with a) subjective effects, b) venous blood level of coca, c) autonomic variables

Estimated Enrollment:	0
Study Start Date:	May 1995

Eligibility

Ages Eligible for Study:	18 Years to 48 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000270

Locations

United States, New York
New York State Psychiatric Institute
New York, New York, United States, 10032

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

New York State Psychiatric Institute

Investigators

Principal Investigator:

Herbert Kleber, M.D.

New York State Psychiatric Institute

More Information

Publications:

ACNP Abstract, 1995. CPDD Abstract, 1996. Society for Nuclear Medicine, 1996. Society for Neuroscience, 1997.

ClinicalTrials.gov Identifier:	NCT00000270 History of Changes
Other Study ID Numbers:	NIDA-09236-5, P50-09236-5
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Cocaine
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Dopamine Uptake Inhibitors
Dopamine Agents

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on February 09, 2012